His addition to the team will strengthen ISPE’s efforts to facilitate industry-wide clarity of new applicable regulations, advising on impacts and resolving towards solutions, and seeking harmonization of regulatory expectations where desired and possible.

BETHESDA, Md. (PRWEB)
April 01, 2020

The International Society for Pharmaceutical Engineering (ISPE) announced today that it has named Jean-François Duliere as a European Regulatory Advisor. Effective 1 April 2020, Duliere takes on this role at ISPE with extensive experience in pharmaceutical regulatory compliance and facilities design for biotechnology, oral solid dosage (OSD), and sterile manufacturing.

“Jean-François brings a wealth of knowledge in an array of critical areas of pharmaceutical manufacturing that are especially pertinent during the current COVID-19 pandemic,” said Tim Howard, President and CEO, ISPE. “His addition to the team will strengthen ISPE’s efforts to facilitate industry-wide clarity of new applicable regulations, advising on impacts and resolving towards solutions, and seeking harmonization of regulatory expectations where desired and possible.”

Duliere has more than 20 years’ experience in the pharmaceutical manufacturing industry. He has worked in the areas of quality control, oral solid dosage forms manufacturing (tablets, capsules), packaging, raw materials production from bacteria growth, industrial development, and dual compartments syringes aseptic filling. He is highly experienced in containment issues for high potent active pharmaceutical ingredients (API), mainly in French companies Laboratoires DEBAT and Laboratoires Fournier.

Duliere has been a consultant for the past 20 years with Technip Life Sciences, a leading provider in the design and construction of pharmaceuticals and biotechnologies facilities, as a senior pharmaceutical expert. He oversees early design stage as conceptual design and has been involved with Good Manufacturing Practice (GMP) design reviews and Regulatory Affairs for most pharmaceutical projects, including:

• 
  Sterile facilities in Europe, China, and North Africa
• Oral Solid Dose facilities in Europe and North Africa
• Vaccine facilities in Europe and China

Since becoming a Member of ISPE in 2002, Duliere has been an active volunteer, participating on numerous committees. He is currently the Chair of the ISPE France Affiliate and Chair of the Regulatory Quality Harmonization Europe-Middle East- Africa (RQHC EMEA) Committee. He holds an Industry Pharmacist PhD.

About ISPE

The International Society for Pharmaceutical Engineering (ISPE) is the world’s largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle. The 18,500 members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world. Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA. Visit ISPE.org for more information.

For more information, contact:

Amy Henry

Marketing Communications Manager

International Society for Pharmaceutical Engineering (ISPE)

Tel: +1-813-960-2105

Email: ahenry@ispe.org

ISPE.org

Share article on social media or email:

Dry-Concepts is providing disinfection services to Florida residents and business owners to combat the spread of the Coronavirus (COVID-19).

“Our team is working diligently to clean and disinfect homes and businesses in response to the COVID-19 pandemic,” said Michael Jatoft, CEO of Dry-Concepts.

FT. LAUDERDALE, Fla. (PRWEB)
April 01, 2020

Dry-Concepts, Florida-based cleaning and restoration company, is providing disinfection services to Florida residents and business owners to combat the spread of the Coronavirus (COVID-19). Dry-Concepts is following guidelines set by both the Environmental Protection Agency (EPA) and the Centers for Disease Control and Protection (CDC) to thoroughly clean, disinfect, and sanitize surfaces that may have been exposed to the virus.

“Our team is working diligently to clean and disinfect homes and businesses in response to the COVID-19 pandemic,” said Michael Jatoft, CEO of Dry-Concepts.

Dry-Concepts is using a multi-step approach to clean potentially affected surfaces. They first use an EPA-registered disinfectant to clean key touch points in a home or business. The tools and materials used meet the specific requirements of the emerging pathogen procedures for enveloped viruses (the class of organism of the SARS & COV-2). This cleaning process targets the areas that are most likely to be exposed to pathogens, including doorknobs, countertops, cupboard handles, computer/electronic equipment, and many more.

After a thorough touch point disinfection, Dry-Concepts uses a proprietary fogging machine to further clean the entire area. The fogging equipment allows the technician to clean and disinfect residual pathogens that may have spread throughout a space. The fog used is a hydrogen peroxide-based disinfectant that is stabilized with silver ions. The result is a deep clean that goes far beyond traditional disinfection measures.

Dry-Concepts provides its cleaning and disinfectant services to both residential and commercial customers. They are fully operational during the COVID-19 pandemic and are considered to be essential service company and are ready to quickly respond to those needing coronavirus disinfection services.

Dry-Concepts is also keeping up to date with the latest coronavirus research and developments from the CDC. The company is dedicated to using the most effective cleaning measures to fight this virus by updating their cleaning techniques as new information is released. With decades of infectious disease control experience, Dry-Concepts understands the threat of this virus and the best possible ways to keep their consumers safe.

About Dry-Concepts:

Dry-Concepts has been in the cleaning and disaster restoration industry for 41 years (Since 1979). Dry-Concepts is using the most up to date and innovative procedures, chemistry and tools that are available to the restoration industry. We are always keeping up to date with new breakthroughs at trade association conventions, continuing education courses for our staff and trade association bulletins. This experience along with the guidance of the CDC/EPA and our own industry trade associations (RIA and IICRC) puts Dry-Concepts in a unique position to help combat the current issues with COVID-19. Dry-Concepts is continually monitoring the latest news and developments that are taking place in regards to COVID-19 and as things change Dry-Concepts will be positioned to respond.

Visit https://www.dryconcepts.com/ to learn more about the company’s COVID-19 disinfection services or call them at 954-370-7778 (Broward County) or 800-248-5071 (Palm Beach/Dade/Orlando).

Share article on social media or email:

Ground glass patterned areas can be seen in the lungs with a chest x-ray, even in the initial stages of COVID-19

We believe that chest X-ray testing in home or at outpatient imaging centers will be critical in our efforts to prioritize care for patients that are most at-risk, and reduce the strain on New York hospitals

NEW YORK (PRWEB)
April 01, 2020

As the number of COVID-19 cases throughout the United States continues to rise, Within Health has pledged to help in the fight against COVID-19 by making radiology imaging more accessible. They have partnered with Zwanger-Pesiri Radiology and mobile X-ray vendors to offer New Yorkers experiencing symptoms the option to get X-rays or CT scans for rapid triage.

“We believe that chest X-ray testing in home or at outpatient imaging centers will be critical in our efforts to prioritize care for patients that are most at-risk, and reduce the strain on New York hospitals,” says Kareem Malek, Chief Operating Officer of Within Health.

Over the past few weeks, studies have emerged that demonstrate the effectiveness of chest X-rays and chest CT scans in determining severity of COVID-19 cases, which will better assist healthcare workers with patient triage. X-rays are the quickest way to assess the severity of cases within a matter of minutes, compared to blood tests or swab-testing methods that can take up to a week to reveal results.

Hospitals and ERs across the United States, and in particular New York, are overwhelmed by the increasing number of COVID-19 patients. The surge is largely due to the lack of available testing, expensive and slow testing methods, and ineffective isolation efforts.

Imaging centers, on the other hand, have seen a 70% decrease in patients. Equipped with the latest diagnostic and imaging equipment as well as board-certified radiologists, these facilities have the potential to be at the forefront of helping to manage the nationwide pandemic crisis by identifying patients that are sick and require further medical care.

Within Health’s platform enables individuals to connect with a team of primary care doctors to quickly determine if a chest X-ray or CT is needed, and if so, schedule the exam and receive their results—all in a timely and efficient manner. The process consists of three simple steps:

Schedule. The patient picks a time for their free virtual consultation with a physician licensed in the state of New York

Virtual Consultation. The physician calls the patient at their preferred time to assess symptoms and determine whether an X-ray or CT scan is appropriate

Exam. The patient visits one of 34 facilities in New York or Long Island, or requests an in-home visit. Results are received on the same day, and a telehealth physician helps the patient navigate their next steps.

For more information, visit covid.seewithin.co.

About Within Health

Within Helth offers a variety of telehealth services, which include facilitating virtual consultations with physicians who ensure that preventive health screens are appropriate and safe to patients. Our mission is to enable convenient, personal and affordable access to preventive health services while also providing an experience that meets the highest standards of quality and comfort.

Share article on social media or email:

This new test from Abbott is simply awesome. A positive result delivered directly to the EHR in just 5 minutes, at the point of care. That speed is a game changer.

ORLANDO, Fla. (PRWEB)
April 01, 2020

Relaymed announced today the launch of their interface for the new molecular point-of-care test from Abbott for the detection of novel coronavirus (COVID-19) that will see test results saved instantly and accurately into the electronic health record (EHR).

Relaymed middleware connects point-of-care testing devices to the EHR, automatically marrying results to orders in real-time, eliminating manual entry and errors.

The new test will run on the Abbott ID NOW platform, one of the most popular devices already in use by Relaymed customers across the US today. Positive results will be delivered in as little as five minutes, whereupon Relaymed will automatically save the result into the EHR. Negative results are delivered within 13 minutes.

This will bring rapid COVID-19 testing to the front lines, into physician offices and urgent care centers, where it is needed. These are the healthcare settings where people show up for care. An accurate, rapid test delivered close to the patient, outside of hospitals, will be transformative to help alleviate the pressure on the healthcare system.

“We’ve worked with Abbott over the weekend to interface with their new COVID-19 test on their ID NOW platform. The speed and agility is testament to both our partnership and the cloud platform we deploy on. This is how we at Relaymed can play our part — our very small part — to help. This new test from Abbott is simply awesome. A positive result delivered directly to the EHR in just 5 minutes, at the point of care. That speed is a game changer,” said Neil Farish, CEO at Relaymed.

Automate COVID-19 testing

Speed, accuracy and reporting of test results are critical in the fight against the COVID-19 pandemic and for the safety of healthcare workers.

COVID-19 is a test result that must be recorded correctly in the patient chart, with no human transcription error sneaking in. Not just for the sake of the individual patient, but also their family, healthcare workers and the wider community. Furthermore, this is a test result that must be made as widely available as fast as possible, with no delay in getting to the electronic patient record, to enable effective population health management.

Automatically and instantly placing test results to the patient chart is the part Relaymed will play to help overcome this COVID-19 challenge.

About Relaymed

Relaymed exists to put lab results automatically, instantly and securely into the EHR. Relaymed makes possible the secure, immediate transfer of data between these two worlds. We’ve built the fastest and most cost-effective middleware solution the ambulatory market was missing. We move and handle point-of-care testing data, enabling dramatic improvements to healthcare delivery through efficiency, speed and simplicity. Now millions of patient test results are transmitted securely and efficiently across a growing network of healthcare organizations leveraging a single connectivity platform, which is compatible with the leading vendors of point-of-care diagnostic testing devices and electronic health records.

Share article on social media or email:

Shady Grove Fertility (SGF) physicians to host weekly virtual fertility events throughout April.

We want to make important decisions about your fertility journey as easy as possible for you, especially during a time where nothing seems easy.

WASHINGTON (PRWEB)
April 01, 2020

During this time of uncertainty, Shady Grove Fertility (SGF) physicians remain true to their commitment to educate and empower the one in eight couples of reproductive age who will struggle to conceive, by offering weekly virtual fertility events (webinars) on a wide range of topics, including getting started, what your menstrual cycle says about your fertility, affording fertility care, IVF, and more.

“Our goal is to always be a trusted go-to resource for patients. Patients have shared with me, those who are using this time to gather information, get their questions answered, and explore their options are finding a renewed sense of calm and control during a period of great uncertainty,” said Naveed Khan, M.D., who will be hosting the ‘What to Expect When You’re Not Expecting’ webinar on April 1.

Attendees will learn what’s involved in a fertility assessment, common causes of infertility, treatments options ranging from basic to more complex, success rates, and much more.

Participants will also learn how to make progress toward building their family amidst the COVID-19 situation.

Participants can join anonymously from the privacy and comfort of home and submit questions of the physicians during a question-and-answer session following the event.

“We want to make important decisions about your fertility journey as easy as possible for you, especially during a time where nothing seems easy,” said Andrea Reh, M.D., who will be hosting the ‘Getting Started on Your Path to Building a Family’ webinar on April 23.

While all SGF in-person and online events are complimentary, interested parties must register to attend by visiting the SGF calendar of events.

April Virtual Fertility Events

April 1 | What to Expect When You’re Not Expecting | Naveed Khan, M.D.

April 7 | In Vitro Fertilization (IVF) | Joseph Osheroff, M.D.

April 9 | Getting Started on Your Path to Building a Family | Naveed Khan, M.D.

April 14 | What to Expect When You’re Not Expecting | Loretta Trumble, CRNP

April 15 | Affording Fertility Care with SGF Financial Programs and Insurance | Jennifer Cockburn, SGF Patient Financial Services Team Lead

April 21 | What Your Menstrual Period Says about Your Fertility | Nicole Doyle, M.D.

April 23 | Getting Started on Your Path to Building a Family | Andrea Reh, M.D.

April 28 | What to Expect When You’re Not Expecting | Isaac Sasson, M.D., Ph.D.

SGF also hosts various virtual physician events on their social channels. Follow SGF on Facebook and Instagram for the latest updates and events.

If you are struggling to conceive, it may be time to consult a fertility specialist. Contact the SGF New Patient Center at 1-877-971-7755 or complete a brief online request form to schedule a virtual fertility consult with an SGF physician. A virtual physician consult is your first step toward pursuing a pregnancy with the help of SGF when the time is right.

To view SGF’s growing library of free, on-demand webinars, E-books, and other education resources on topics such as endometriosis, PCOS, low-tech treatment options, weight and infertility, and much more, visit http://www.shadygrovefertility.com/resources/educational-resources.

About Shady Grove Fertility (SGF)

SGF is a leading fertility and IVF center of excellence with more than 85,000 babies born and counting. With 38 locations throughout FL, GA, MD, NY, PA, VA, D.C., and Santiago, Chile, we offer patients virtual physician consults, individualized care, accept most insurance plans, and make treatment affordable through innovative financial options, including treatment guarantees. More physicians refer their patients to SGF than any other center. Call 1-888-761-1967 or visit ShadyGroveFertility.com.

Share article on social media or email:

Sharon Kleyne, Founder of Bio Logic Aqua® Research

GRANTS PASS, Ore. (PRWEB)
April 01, 2020

Air Date: 30 March 2020

Guest: Dr. Angela Zeng, lead physician with Ascentage Pharma, a global biopharmaceutical company headquartered in Washington D.C.; Vice-President of Chinese Biopharmaceutical Association; former oncology faculty at the Johns Hopkins University where she earned her post-doctoral degree; was an attending surgeon with more than 10 years of intensive experience in OB&Gyn.

https://www.voiceamerica.com/episode/122682/self-protection-during-covid-19

*

During the virus pandemic, Bio Logic Aqua® Research Water Life Science® will be providing regular updates at http://www.sharonkleynehour.com/Coronavirus.php. Also, please watch this educational video about hand washing: https://www.housebeautiful.com/lifestyle/a31903011/black-paint-white-gloves-viral-video-shows-hand-washing-technique/

*

For the last thirteen years, Global Health Olympics™ inventor and talk radio on VoiceAmerica host Sharon Kleyne has educated people around the world about the importance of body water loss evaporation and good health self-protection.

“You are like a sponge when you’re born,” shares Kleyne in her Commentary. “Nature takes its time, and then you are born to live in the water vapor of the atmosphere of earth and the solar system. That energy,” Kleyne continues, “is like a battery. You’re electrically charged.”

Now we are faced with a new, virulent virus, Coronavirus. “It’s a whole new virus,” says Kleyne. “We’re learning with each other. Researchers and scientists have to take their time to get a vaccine right and while they’re learning, we need to join up together and practice good Global Health Olympics™. How you breathe, sleep, eat and exercise are all so important to maintaining good health.”

Water Life Science® researcher Kleyne’s guest, Dr. Angela Zeng, grew up and was educated in China. She is the lead physician with Ascentage Pharma, a global biopharmaceutical company headquartered in Washington D.C. and Vice-President of Chinese Biopharmaceutical Association. Before becoming a research pharmacologist, Zeng was on the oncology faculty at the Johns Hopkins University where she earned her post-doctoral degree. Zeng was also an attending surgeon with more than 10 years of intensive experience in OB&Gyn.

Responding to Kleyne’s question about her current project, Zeng says she is working on new medicines for cancer patients with a special focus on ovarian cancer. She explains how drug development goes through at least four rigorous test cycles or phases before being approved for general use.

Kleyne asks if it’s true that all humans should drink a lot of water every day to flush toxins from the body and stay hydrated. Zeng agrees, saying “I believe water is very important for our bodies.”

“I’ve always thought that the body makes the decision,” adds Kleyne, “not the person. The body is the decider telling people to drink more water and participate in the Global Health Olympics™. People need to be educated, even the physicians, even the scientists, about the importance of water today.”

Commenting on the dangers of COVID-19, Zeng says “Everyone needs to work together. It’s more contagious than the common flu. The COVID-19 virus seems to last longer on hard surfaces.” Zeng also offers tips for hand washing. If one uses hand sanitizers, she urges a product that is at least 60 percent alcohol. If washing hands with soap, Zeng teaches that one should keep the soap working into the hands for at least twenty seconds before rinsing. Zeng also agrees with Kleyne that people should strive to eat a balanced diet featuring enough protein and vegetables. “We need to boost our immune systems to fight the virus,” says Zeng. “Protein is critical to this process.”

Kleyne also asks if the eyes and dry eyes are especially affected by COVID-19, to which Zeng replies “No. There are no virus-specific symptoms found in the eyes.”

Laughing together, Kleyne “assigns” Dr. Zeng (since she lives and works near Washington, D.C.) to drive around reminding physicians, researchers and politicians to start talking about the importance of water. Kleyne also reminds everyone “to put a child’s heart in your hands.”

*

If you would like to listen to the internationally syndicated The Power of Water® & Your Health sponsored by Nature’s Tears® EyeMist® on VoiceAmerica assisted by Program Director Rose Hong, founder and director of Global Dragon TV in Washington, D.C., featuring Dr. Angela Zeng, lead physician with Ascentage Pharma, a global biopharmaceutical company headquartered in Washington D.C. and Vice-President of Chinese Biopharmaceutical Association and Global Health Olympics™ Water Life Science® educator and evaporative dry eye and body researcher Sharon Kleyne as they discuss viruses, infectious disease, proactive care, health habits, teamwork, research, ovarian cancer, education, water and evaporation, follow this link:

https://www.voiceamerica.com/episode/122682/self-protection-during-covid-19

*

If you would like to watch a very brief, entertaining educational film that demonstrates the application of the new Dry Eye Solution® technology Nature’s Tears® EyeMist®, sponsor of Sharon Kleyne’s talk radio program, go here: https://www.youtube.com/watch?v=l0gOr8TB45U

Share article on social media or email:

“This designation recognizes Dr. Michael Belsante as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson

PLEASANTON, Calif. (PRWEB)
April 01, 2020

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Michael Belsante M.D., Urology Associates, PC in Nashville, TN, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Belsante has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“This designation recognizes Dr. Michael Belsante as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “We are pleased to see the continued acceptance of the UroLift System as a standard of care treatment that may allow men to discontinue the use of BPH medications and improve their quality of life.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504 nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Foodservice is our family and our focus as a company,” said Steven Getraer, President of ComplianceMate™. “We want to make sure that we help find a way for our family and those it serves to stay safe in these challenging times.

LAWRENCEVILLE, Ga. (PRWEB)
April 01, 2020

As the impacts of the novel coronavirus (COVID-19) increase and spread across the country and throughout the world, foodservice establishments are diligently working to protect their guests and staff. Yet, the safest and best practices to deal with COVID-19 are evolving almost daily, and implementing and adhering to rapidly changing guidelines and best practices is a 24/7 job.

ComplianceMate™, the global leader in enterprise food safety management tools, recognizes these challenges and is ready to help.

Starting Wednesday, April 1, 2020, foodservice companies can go HERE and get ComplianceMate’s free web-enabled app ComplianceMate C19. It is accessible via any device and was created to support efforts to control the unique, constantly evolving recommendations and requirements for COVID-19 safety.

The app will automatically keep foodservice operators current on guidelines from the Centers for Disease Control (CDC), the U.S. Food and Drug Administration (FDA), and the U.S. Department of Health and Human Services (HHS) through always up-to-date checklists and workflows. At launch, the app will include guidelines for employee wellness checks, cleaning/sanitation checks, personal hygiene advice, and procedures for returning to work after an employee tests positive.

Simultaneously, the app will also record actions taken by the employee, so managers can quickly and easily confirm compliance with COVID-19 measures. The app can be used by c-stores, grocery, QSR, fast food, and restaurants offering third-party delivery.

“We want to help the foodservice industry successfully navigate through this trying time, so we’ve worked with leading public health professionals from around the country to develop this app,” says Tom Woodbury, VP-National Accounts for ComplianceMate™. “As best practices continue to evolve, the app will be updated to reflect those changes.”

For example, on February 11th, the CDC stated that an employee testing positive for COVID-19 needed negative results from “at least 2 consecutive sets of nasopharyngeal and throat swabs collected at least 24 hours apart” before ending home isolation. ComplianceMate C19 captures this requirement. As the outbreak progresses, this requirement may change, and the app will react quickly to reflect any new protocol(s) as changes impacting foodservice arise.

“It’s a challenge for restaurants to stay up to date on the constantly evolving guidelines,” says Cindy Rice, President of Eastern Food Safety. “This app will be updated as guidelines change, so foodservice can stay up to date on the latest CDC and FDA recommendations.”

“Foodservice is our family and our focus as a company,” said Steven Getraer, President of ComplianceMate™. “We want to make sure that we help find a way for our family and those it serves to stay safe in these challenging times.”

For more information on installing the free web app, click here: ComplianceMate C19.

ABOUT COMPLIANCEMATE™:

ComplianceMate has streamlined HACCP compliance checklist and cooler monitoring for thousands of restaurant locations across the US, Canada, and the UK. Using the ComplianceMate family of mobile apps, users can complete checklists for any HACCP or brand-specific compliance standards, even incorporating photos and videos for visual documentation, from their personal devices, including smartphones and tablets. For more information, please visit ComplianceMate.com.

Share article on social media or email:

These new additions will further bridge the multi-disciplinary gap to provide even more objective and comprehensive conclusions to be drawn without any negative impact to the study workflow or participant compliance.

CARLSBAD, Calif. (PRWEB)
April 01, 2020

Salimetrics’ original panel of cytokines validated in saliva integrated the four popular cytokines IL-1 Beta, IL-6, IL-8, and TNF-Alpha so that researchers could immediately study inflammation and immune function using non-invasive saliva sampling. These cytokines are closely related in function and more in line with an acute inflammatory response. Subsequently, Salimetrics validated IFN-γ, IL-2, IL-10, IL-12p70, and IL-13, some of which are anti-inflammatory, critical for more chronic conditions of immune pathology or produced in response to ongoing infections.

Now, the newly validated cytokine markers IL-5, IL-7, and IL-17A further expand the list of cytokines that can be accurately tested in saliva. Salivary cytokine testing from the Salimetrics SalivaLab will aid researchers in building a critical foundation of peer-reviewed research and accelerate the evolution of new discoveries. “The biological relationships combined with the continued interest in salivary cytokines by investigators underpins the necessity for assays that work together to expand the cutting edge of salivary cytokine research,” says Supriya Gaitonde, Ph.D., Salimetrics Senior Applications Scientist. “By combining additional cytokines, researchers are now able to obtain a more complete picture with respect to how the body responds to inflammation and immune function.”

“Today, the ideal solution for research critically focused on multiple analytes being assayed from the same sample just got even better,” says Steve Granger, Ph.D., Salimetrics CSO. “These new additions will further bridge the multi-disciplinary gap to provide even more objective and comprehensive conclusions to be drawn without any negative impact to the study workflow or participant compliance.”

Human Interleukin-17A (IL-17A) is an important marker for chronic inflammation. In fact, elevated levels of IL-17A have been associated with many chronic inflammatory and autoimmune diseases including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), psoriasis, multiple sclerosis (MS), and systemic lupus erythematosus (SLE). IL-17A is also elevated in fluids from the lungs of patients with asthma and COPD. It comes as no surprise that IL-17A is a popular drug target and drugs (ixekizumab, secukinumab) have been approved by the FDA for psoriasis, psoriatic arthritis and are being used as off label therapeutics for treating RA, IBD, and SLE. More specific to the salivary glands, IL-17A is also involved in Sjogren’s syndrome.

Human Interleukin-5 (IL-5) mainly drives the maturation and maintenance of eosinophils and antibody secreting B cells. Dysregulation of IL-5 is associated with eosinophilia, atopic dermatitis, and pulmonary fibrosis. IL-5 is also expressed in the mast cells of asthmatic airways and is a promising drug target for the treatment of asthma. In fact, three therapeutic monoclonal antibodies (mepolizumab, benralizumab and reslizumab) have received FDA approval targeting IL-5 to treat severe eosinophilic asthma. Measuring IL-5, in combination with IL-13 and TNF, in oral fluid is of interest for asthma researchers since fluids from the lung exchange with saliva and levels are elevated in asthmatic patients.

Human Interleukin-7 (IL-7) activity is important for every stage of T cell development, survival of naïve T cells, and generation and maintenance of CD4 and CD8 memory. Pathologies associated with IL-7 are those mediated by dysregulation of lymphoid function such as autoimmune diseases (diabetes and multiple sclerosis) and chronic inflammatory diseases (rheumatoid arthritis and inflammatory bowel disease). IL-7 signaling is also associated with lymphoid leukemias.

The Salimetrics Cytokine Panel will continue to feature the core-4 cytokines (IL-1 Beta, IL-6, IL-8, and TNF-Alpha), but now includes the ability to add-on up to 8 additional cytokines, including salivary; IFN-Gamma, IL-2, IL-5, IL-7, IL-10, IL-12p70, IL-13, and IL-17A. This means that researchers can now measure up to 12 cytokines from one saliva sample at Salimetrics’ SalivaLab, which makes Salimetrics’ panel the most robust salivary cytokine panel available. This expansion reinforces Salimetrics’ commitment to further revolutionize salivary cytokine testing and provide researchers access to validated methodologies that deliver precise and reproducible results.

“We’re happy to offer this expanded service to the family of Salivary Bioscience researchers,” says Dr. Granger, “It shows that we are actively committed to providing the best and most accurate salivary bioscience methods to researchers around the world – and we make it as easy as picking up the phone or sending an e-mail.”

About Salimetrics

Salimetrics’ assay kits and CLIA-certified testing services are used to measure salivary analytes related to stress, behavior and development, inflammation, sleep, reproduction, health and immune function. Founded in 1998 by Douglas A. Granger, Ph.D., Salimetrics, LLC supports CROs, pharmaceuticals, academic researchers and the immunodiagnostic industry around the world with innovative immunoassay products, non-invasive saliva collection methods, and laboratory testing services.

Share article on social media or email: